Rapid prototyping in pharma: How to test, learn and move faster

Rapid prototyping is the practice of building a simplified, testable version of a digital experience before committing to full development. That might be a clickable journey, a working concept, or a simplified product flow. Something real enough to put in front of users, learn from, and improve.

The goal isn't to build something perfect. It's to build something useful enough to test your assumptions and answer the right questions early — before time and money are spent on the wrong solution.

In digital health and pharma, those questions tend to cluster around a few core areas:

• Can HCPs or patients complete the task they came to do?
• Does the content and messaging land clearly?
• Where does the journey create friction or confusion?

Answering these questions with evidence from real users, in realistic conditions is what separates well-built digital products from those that require expensive rework post-launch.

Digital ambition across pharma has shifted considerably. AI-driven personalisation, omnichannel HCP engagement, connected patient ecosystems: the strategic direction is clear enough.

But many teams are still navigating real structural constraints: platforms that don't connect cleanly, fragmented customer journeys, content that doesn't land with the people it's intended for. Add slow internal approval cycles and you have conditions where launching anything, let alone iterating on it, takes far longer than it should.

Rapid prototyping doesn't remove those constraints. It gives teams a more disciplined way to make decisions within them. Instead of committing upfront, you create something lightweight, test it with real users, and learn what works. You're not removing risk; you're moving it earlier, when it's far cheaper to manage.

In practice, rapid prototyping typically involves three stages: build, test, and iterate.

Build a lightweight prototype

Tools like Figma allow teams to simulate real desktop and mobile interactions without writing a line of code. Prototypes don't need to be polished or complete; they need to be functional enough to expose the assumptions underneath the design. A medical information journey, a patient support tool, a new HCP portal: all can be prototyped quickly and cheaply at this stage.

Test with real users

Even small-scale user testing, typically five to eight participants, surfaces patterns that internal review rarely catches. Where people get stuck, what they skip, how they interpret what they're seeing. A journey that looks coherent internally often doesn't hold up when someone tries to use it under real conditions.

Iterate based on evidence

Findings from testing feed directly back into the design. Assumptions that don't hold get revised. What remains gets refined. The cycle continues until the experience is ready for broader investment or development.

There's a persistent assumption in pharma that testing and iteration create regulatory risk. In practice, the opposite tends to be true.

When teams don't test early, decisions default to stakeholder opinion. Issues surface late, after content has entered MLR (medical, legal, regulatory) review, after a build is underway, after budgets are committed. Fixing them at that stage is expensive and slow.

Rapid prototyping moves the risk earlier. It lets teams validate user needs and sense-check content before anything enters formal review. It also gives MLR stakeholders something concrete to respond to, which tends to produce more specific, grounded feedback than abstract debate about hypothetical designs.

The result is fewer late-stage surprises and a smoother path from concept to launch.

A common concern in pharma digital design is how to meet regulatory requirements without sacrificing usability. Safety information, fair balance, and product detail all need to be present. That's not in question.

What is often more flexible than teams assume is how that information is structured and delivered.

Prototyping creates a space to explore that flexibility without risk. Rather than debating hypothetical approaches in the abstract, teams can test them in context: how safety content is introduced, how information is layered, how users move between different content types.

Done properly, it shifts compliance from a final approval gate into something considered throughout the design process. That produces better outcomes: experiences that meet regulatory requirements and actually work for the people using them.

Speed in pharma rarely comes from individual teams working harder. It comes from reducing the gaps between them.

Design sprints are one of the most effective ways to do that. In a short, focused period, typically three to five days, cross-functional teams move from an initial idea to a testable prototype. More importantly, they do it together.

That typically means bringing commercial, UX, medical and regulatory stakeholders into the process from the start. When that happens, alignment builds naturally as the work progresses. Late-stage feedback that fundamentally changes direction, one of the most common blockers in pharma digital projects, becomes far less likely.

There's still a significant gap in many pharma digital experiences between what organisations want to communicate and what users actually need.

HCPs aren't browsing. They're answering a specific clinical question, under time pressure. Patients are often navigating uncertainty and need clarity, not layered complexity. These realities are well understood in principle, but they're frequently lost in the translation from strategy to execution.

Rapid prototyping makes that gap visible. Even small-scale testing reveals where people struggle, what they ignore, and how they interpret what they're seeing. Those moments, where the gap between design intent and user behaviour becomes undeniable, are where real product decisions should be made.

The teams making the most meaningful progress in 2026 aren't treating prototyping as a single phase at the start of a project. They're using it as part of an ongoing cycle: testing ideas early, building on real behavioural evidence, and iterating based on what they learn.

That requires a different operating mindset: less focus on delivering a finished product in one go, more on creating something that can improve continuously. It's a shift that takes time to embed, but the compounding effect on quality and speed is significant.

Rapid prototyping works best when it's connected to a broader strategic framework, not treated as a standalone exercise.

At Graphite, it sits alongside UX strategy, where the right problems are defined, and user research, where real needs are understood. It feeds into design systems that allow successful ideas to scale consistently, and into ongoing optimisation where performance is measured and improved over time.

Without that surrounding context, prototyping can become a useful but isolated activity. With it, it becomes a practical mechanism for making better decisions throughout the full lifecycle of a digital product.

There's no shortage of ideas in pharma and digital health. The challenge is deciding which ones deserve investment, and moving them forward with genuine confidence.

Rapid prototyping offers something more grounded than intuition or internal consensus: evidence, from real users, in realistic conditions, before significant commitments are made.

In a sector where the cost of getting it wrong is high and the pressure to move fast is real, that discipline is worth building into how teams work.

What is rapid prototyping in pharma? 

Rapid prototyping in pharma is the practice of building a simplified, testable version of a digital experience, such as an HCP portal, patient support tool, or medical information journey, before committing to full development. It allows teams to validate user needs, test assumptions, and identify issues early, when they're cheapest to fix.

How does rapid prototyping reduce risk in regulated environments? 

By testing with real users before content enters formal MLR review, teams can surface and address usability and comprehension issues early. This reduces the likelihood of costly late-stage changes and gives regulatory stakeholders more concrete material to review, leading to more efficient sign-off processes.

What tools are used for rapid prototyping in digital health? 

Figma is the most widely used tool for creating interactive prototypes in digital health. It allows teams to simulate real desktop and mobile interactions without development resource, making it fast and cost-effective to test and iterate on digital experiences.

How long does a rapid prototyping sprint take? 

A focused design sprint, moving from initial idea to testable prototype, typically takes three to five days with the right cross-functional team. More complex journeys may require additional rounds of iteration, but meaningful learning can be achieved quickly even in tight timeframes.

Is rapid prototyping suitable for HCP and patient-facing experiences? 

Yes. Rapid prototyping is particularly well-suited to HCP and patient-facing digital experiences, where getting the user journey right matters significantly. Testing with representative users early helps teams understand how HCPs find clinical information, how patients navigate support tools, and where the experience creates unnecessary friction.